Bio-Techne Corporation’s Stock Price Drops to $71.77, Reflecting a 2.18% Decrease

Bio-Techne Corporation (TECH)

71.77 USD -1.60 (-2.18%) Volume: 0.83M

Bio-Techne Corporation’s stock price stands at 71.77 USD, experiencing a decrease of 2.18% this trading session with a trading volume of 0.83M, reflecting a YTD performance dip of 6.99%, highlighting the need for potential investors to assess the volatility and future prospects of TECH stocks.

Latest developments on Bio-Techne Corporation

Today, Bio-Techne Corp’s stock price experienced movement following the release of their fourth quarter fiscal 2024 results. The company’s earnings call met expectations, with profits on point but revenue slightly missing projections. Despite this, DekaBank Deutsche Girozentrale increased their position in Bio-Techne Co., showing confidence in the company’s future growth. Analysts at Robert W. Baird raised the price target for Bio-Techne (NASDAQ: TECH) to $82.00, while Royal Bank of Canada trimmed their target price to $70.00. Overall, the market reacted with a 6.2% decrease in Bio-Techne’s stock price, reflecting both positive and negative sentiments towards the company’s performance.

Bio-Techne Corporation on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been closely following Bio Techne Corp, a biotech firm specializing in protein and cell-based research. According to research reports, Bio Techne Corp recently reported their third quarter 2024 earnings with strong performance, indicating stabilization in their financial circumstances. The company’s 2% year-over-year organic revenue growth exceeded expectations, suggesting potential expansion as biotech funding and macroeconomic challenges in China stabilize.

Another report from Baptista Research highlights Bio Techne Corp‘s resilience amidst economic challenges. Despite facing a 2% organic revenue decline in the second quarter of fiscal year 2024, the healthcare company’s core portfolio has shown consistent growth potential with a 7% average growth rate over the last decade. The earnings were impacted by headwinds such as a cautious biopharma spending environment, a tougher macroeconomic climate in China, and lowered demand from OEM customers. Analysts remain optimistic about Bio Techne Corp‘s long-term prospects despite these challenges.

A look at Bio-Techne Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bio Techne Corp has a promising long-term outlook. With a high Momentum score of 5, the company is showing strong positive price trends and investor sentiment. This indicates that Bio Techne Corp is likely to continue to perform well in the market in the future. Additionally, the Growth score of 3 suggests that the company has good potential for future expansion and development.

While Bio Techne Corp has solid Momentum and Growth scores, its Value, Dividend, and Resilience scores are more moderate. This indicates that the company may not be as undervalued compared to its peers, and its dividend payouts and financial stability may not be as strong. However, overall, Bio Techne Corp‘s Smart Scores suggest a positive outlook for the company’s future performance in the biotechnology industry.

### Bio-Techne Corp develops, manufactures and sells biotechnology products and clinical diagnostic controls. The Company specializes in proteins, cytokines, growth factors, immunoassays and small molecules. ###

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma